Schering-Plough (US)

Schering-Plough was a leading US healthcare company with a broad portfolio of pharmaceutical and over the counter products. It enjoyed considerable success in the late 1990s with the non-drowsy antihistamine Claritin. However, between 2001 and 2003 the company suffered a series of dramatic reversals of fortune, not least the collapse in sales of Claritin following the expiry of its patent. A new management team began a complete overhaul of the business in 2003, kickstarting the company's drug pipeline and establishing a number of partnership agreements, including a deal in 2004 to take over US sales and marketing duties for Bayer's drug portfolio. In 2009, the company agreed a deal to be acquired by larger competitor Merck & Co, with whom it already operated a worldwide joint venture to market asthma and anti-cholesterol products.

Click here for the Adbrands.net profile (subscribers only); or subscribe to Adbrands.net here. Adbrands Company Profiles provide a detailed analysis of the history and current operations of leading advertisers, agencies and brands worldwide, and include a critical summary which identifies key strengths and weaknesses. Adbrands Account Assignments tracks account management for the world's leading brands and companies, including details of which advertising agency handles which accounts in which countries for major markets.

Competitors: see Pharmaceutical Sector index for other companies

The Adbrands Company Profile of Schering-Plough summarises the company's history. Subscribers may access the following website links:

Schering-Plough website

Claritin	Lotrimin
Intron	Afrin
Dr Scholl's	Coppertone
Follistim	Zemuron
NuvaRing	Integrilin
Implanon	Asmanex
Bain de Soleil	Zetia
Clarinex	Nasonex
Temodar	Vytorin

Click HERE to subscribe to Adbrands.net and access the profile and website links